Objective To assess the effectiveness and safety of Weifuchun for chronic atrophic gastritis. Methods Trials were located through electronic searches of The Cochrane Library (Issue 3, 2007), EMbase (1974 to June 2007), PubMed (1966 to June 2007), CBM (1978 to June 2007), CNKI (1994 to June 2007) and VIP (1989 to June 2007). Randomized controlled trials (RCTs) and quasi-RCTs of Weifuchun for chronic atrophic gastritis were included. A critical quality assessment and Meta-analysis were performed for the included studies. RevMan 4.2.2 was used for statistical analysis. Results A total of 8 trials involving 816 patients were included. Meta-analysis showed that compared with the control group, Weifuchun for the CAG treatment group had superiority in many aspects such as effective rate according to Gastroscopy (RR 1.54 and 95%CI 1.31 to 1.81), effective rate according to Patho-check (RR 1.99 and 95%CI 1.54 to 2.58), adverse events, remission rate based on clinical symptoms (RR 1.47 and 95%CI 1.30 to 156), remission rate based on a single symptom, curative effect with IM/ATP, HP darkening rate (RR 1.26 and 95%CI 1.02 to 1.56), situation of hemoglobin change and so on. No RCTs were found to describe the safety of Weifuchun for CAG. Conclusion Because of low quality and small samples, there is no enough evidence on Weifuchun for chronic atrophic gastritis. More largescale multi-center randomized trials are needed to investigate the role of Weifuchun for chronic atrophic gastritis.